Please join us for an Open Scientific Discussion (OSD) hosted by the AAPS Gene and Cell Therapy Products (GCTPs) Community on May 2, 2024, 12 pm – 1 pm EDT on the following topic:
Secondary malignancies post-CART cell therapy: Clinical and Regulatory Perspectives
- Are you aware of the recent FDA requirement of class wide boxed warning on all commercial CAR-T therapies?
- What do we know and not know about second malignancies?
- What's your experience in secondary malignancies and CART cell therapy?
Panelists:
Bruce Levine (Professor, Univ. PENN)
Nicole Verdun (Super Office Director, FDA, CBER)
Organized by:
Vibha Jawa (BMS), Yan Ni (Passage Bio), Yanmei Lu (Sangamo)
We start at 12:00 PM EDT sharp. To avoid interruptions, please dial in before noon and mute yourself until Q&A starts.
(Please remain on mute unless asking questions)
When: Thursday May 2, 12:00 – 1:00 PM EDT
Where: Please join from your computer, tablet or smartphone.
https://meet.goto.com/505947717
You can also dial in using your phone.
United States: +1 (646) 749-3122
Access Code: 505-947-717
Join from a video-conferencing room or system.
Dial in or type: 67.217.95.2 or inroomlink.goto.com
Meeting ID: 505-947-717
Or dial directly: [email protected] or 67.217.95.2##505947717
New to GoToMeeting? Get the app now and be ready when your first meeting starts:
https://meet.goto.com/install
Please feel free to share with colleagues who may be interested in this topic.
Thank you,
The AAPS GCTPs Communities Leadership Team
------------------------------
Karen Quadrini, PhD
Director, Clinical Biomarkers
Prothena Biosciences
Brisbane, CA
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------